Literature DB >> 2893273

Regulation of hypothalamic beta-endorphin and dynorphin release by corticotropin-releasing factor (CRF).

O F Almeida1, K E Nikolarakis, A Herz.   

Abstract

Synthetic rat-human corticotropin releasing-factor (CRF), in doses between 10(-12) M and 10(-8) M, significantly stimulates the release of immunoreactive beta-endorphin and dynorphin-A from rat hypothalamic slices superfused in vitro. With prolonged exposure to CRF, there is a reduction in the release of both opioids which can be reversed by the addition of naloxone. The latter result indicates the involvement of autoregulatory mechanisms in the control of opioid neuronal function.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2893273

Source DB:  PubMed          Journal:  NIDA Res Monogr        ISSN: 1046-9516


  4 in total

1.  Next generation effects of female adolescent morphine exposure: sex-specific alterations in response to acute morphine emerge before puberty.

Authors:  Fair M Vassoler; Nicole L Johnson-Collins; Lindsay M Carini; Elizabeth M Byrnes
Journal:  Behav Pharmacol       Date:  2014-04       Impact factor: 2.293

Review 2.  Role of kappa-opioid receptors in stress and anxiety-related behavior.

Authors:  Ashlee Van't Veer; William A Carlezon
Journal:  Psychopharmacology (Berl)       Date:  2013-07-09       Impact factor: 4.530

3.  Interaction of CRF and kappa opioid systems on GABAergic neurotransmission in the mouse central amygdala.

Authors:  Maenghee Kang-Park; Brigitte L Kieffer; Amanda J Roberts; George R Siggins; Scott D Moore
Journal:  J Pharmacol Exp Ther       Date:  2015-09-08       Impact factor: 4.030

4.  Estrogen augments hypothalamicβ-endorphin secretion and activates an inhibitoryβ-endorphin short-loop feedback system.

Authors:  S A Frautschy; D K Sarkar
Journal:  Endocrine       Date:  1995-04       Impact factor: 3.633

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.